The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Rapid Molecular Flu Testing Platforms Market Grow Between 2026 And 2030?
The rapid molecular flu testing platforms market has demonstrated substantial growth in recent years. This market is anticipated to expand from $2.71 billion in 2025 to $2.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.3%. Historically, this expansion has been driven by factors such as the increasing prevalence of influenza, the need for swift diagnostic results, the adoption of RT-PCR technologies, the development of hospital and clinical testing infrastructure, and a heightened awareness of infectious disease management.
The rapid molecular flu testing platforms market size is anticipated to experience significant growth in the coming years. It is forecast to grow to $4.47 billion by 2030, achieving a compound annual growth rate (CAGR) of 10.6%. The expansion during the forecast period can be attributed to the incorporation of AI and IoT for rapid diagnostics, the increasing availability of portable and point-of-care platforms, the creation of multiplex and high-throughput testing systems, rising investment in molecular diagnostic technologies, and the uptake of home-based and decentralized testing. Prominent trends for the forecast period include the swift expansion of point-of-care testing, multiplex molecular diagnostics, integration with laboratory information systems, automated sample processing, and high-throughput testing platforms.
Access Your Free Sample Report For In-Depth Market Analysis:
What Leading Drivers Are Supporting The Rapid Molecular Flu Testing Platforms Market Expansion?
The increasing occurrence of seasonal and pandemic influenza outbreaks is anticipated to drive the expansion of the rapid molecular flu testing platforms market. These outbreaks refer to the recurring or widespread presence of influenza infections caused by existing or novel influenza viruses. The escalating frequency and intensity of these outbreaks are influenced by factors such as high population mobility, extensive international travel, urban density, viral mutations, and inadequate vaccination coverage, all of which facilitate the rapid transmission of the virus. Rapid molecular flu testing platforms are crucial in managing seasonal and pandemic influenza outbreaks by enabling swift and highly accurate detection of influenza viruses, thereby supporting timely clinical decisions, early treatment initiation, and effective infection control measures. For instance, in February 2026, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, for the 2025–2026 influenza season, influenza infections in the United States resulted in approximately 290,000–450,000 hospitalizations and 34,000–53,000 deaths, emphasizing the substantial public health and economic burden of the disease. Therefore, the rising global incidence of seasonal and pandemic influenza outbreaks is fostering the growth of the rapid molecular flu testing platforms market.
How Are Different Segments Classified In The Rapid Molecular Flu Testing Platforms Market Segment Analysis?
The rapid molecular flu testing platforms market covered in this report is segmented –
1) By Product Type: Benchtop Platforms, Portable Platforms, Other Product Types
2) By Sample Type: Nasopharyngeal Swabs, Throat Swabs, Saliva, Other Sample Types
3) By Technology: Reverse Transcription Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Based, Other Technologies
4) By Distribution Channel: Direct Sales, Distributors, Online Sales, Other Distribution Channels
5) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users
Subsegments:
1) By Benchtop Platforms: Multiplex Testing Platform, High Throughput Platform, Automated Sample Processing Platform, Standard Laboratory Platform
2) By Portable Platforms: Handheld Testing Platform, Point Of Care Testing Platform, Battery Operated Portable Platform, Field Deployable Platform
3) By Other Product Types: Integrated Workflow Platform, Compact Diagnostic Platform, Rapid Screening Platform, Custom Configured Platform
What Trends Are Shaping The Future Of The Rapid Molecular Flu Testing Platforms Market?
Major companies operating in the rapid molecular flu testing platforms market are increasingly concentrating on developing advanced multiplex molecular solutions, like temperature-activated generation of signal (TAGS) technology, to allow for high-throughput and simultaneous identification of multiple respiratory pathogens, such as influenza A and B, from a single patient sample. TAGS technology, an advanced PCR innovation, enables the differentiation of multiple genetic targets within a single fluorescence channel, yielding up to 15 diagnostic results in one test well. For example, in September 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, launched the cobas Respiratory flex test. This test permits the rapid detection of up to 12 respiratory viruses, including influenza A and B, when used on Roche’s cobas 5800, 6800, and 8800 high-throughput molecular systems. This solution aids flexible, syndromic panel testing with high throughput, optimizing laboratory workflows and resources while promoting accurate and timely diagnosis of respiratory infections.
Who Are The Companies Driving Activity In The Rapid Molecular Flu Testing Platforms Market?
Major companies operating in the rapid molecular flu testing platforms market are Roche Diagnostics, Thermo Fisher Scientific, Abbott Laboratories, Siemens Healthineers, Becton Dickinson (BD), bioMérieux, Bio-Rad Laboratories, Qiagen N.V., Seegene Inc., BioPerfectus, Fapon Biotech, Visby Medical, Vircell S.L., QuantuMDx Group, Altona Diagnostics, Creative Diagnostics, Princeton BioMeditech Corporation, Credo Diagnostics, Genetic Signatures Ltd, AccuBioTech, Kogene Co. Ltd., Ameritek Inc., Alpha Diagnostic Intl, Medlere Ltd, ProtonDx Ltd.
Get The Full Rapid Molecular Flu Testing Platforms Market Report:
Which Region Leads The Rapid Molecular Flu Testing Platforms Market In Overall Market Size?
North America was the largest region in the rapid molecular flu testing platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rapid molecular flu testing platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Rapid Molecular Flu Testing Platforms Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Rapid Molecular Flu Testing Platforms Market 2026, By The Business Research Company
connected health personal medical devices market report 2026
contract sterilization market report 2026
https://www.thebusinessresearchcompany.com/report/contract-sterilization-global-market-report
orthotic insole 3-d printer market report 2026
https://www.thebusinessresearchcompany.com/report/orthotic-insole-3-d-printer-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model